MedCity News June 21, 2022
Frank Vinluan

Human Longevity, Inc., a startup founded by genomics pioneer J. Craig Venter, plans to join the public markets via a SPAC merger. If the business combination closes, HLI would receive about $345 million for continued commercialization of its platform that uses genomics, AI, and other technologies for early disease detection and other strategies intended to help people live longer.

Human Longevity, Inc., (HLI), a company aiming to use genomic insights to help people live longer, has found a way to extend its corporate life. The firm has reached a merger deal that will take the company public and infuse it with $345 million to bring its life-extending approach to more users in the U.S. and around the world.

San Diego-based...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Investments, Mergers & Acquisitions / JV, Pharma / Biotech, Precision Medicine, Trends
Estonian Biobank to Sequence 10,000 Genomes as Part of Precision Medicine Project
Precision Immune Start-Up Mirador Launches with $400M+
The future of companion diagnostic (CDx) development: Why commercialization is key
STAT+: Drug development was once a marathon. New tools and timelines are turning it into a sprint
Precision Medicine Startup Mirador Unveils $400M for R&D of New I&I Drugs

Share This Article